• Medientyp: E-Artikel
  • Titel: Prevalence of Neutralizing Antibodies to Canine Distemper Virus and Response to Vaccination in Client-Owned Adult Healthy Dogs
  • Beteiligte: Bergmann, Michèle [VerfasserIn]; Freisl, Monika [VerfasserIn]; Zablotski, Yury [VerfasserIn]; Khan, Md Anik Ashfaq [VerfasserIn]; Speck, Stephanie [VerfasserIn]; Truyen, Uwe [VerfasserIn]; Hartmann, Katrin [VerfasserIn]
  • Erschienen: Basel: MDPI, [2023]
  • Erschienen in: Viruses ; 13,5, (2021)
  • Sprache: Englisch
  • Schlagwörter: protection ; CDV ; vaccine ; antibody titer ; virus neutralization
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Re-vaccinations against canine distemper virus (CDV) are commonly performed in 3-year intervals. The study’s aims were to determine anti-CDV antibodies in healthy adult dogs within 28 days of vaccination against CDV, and to evaluate factors associated with the presence of pre-vaccination antibodies and with the antibody response to vaccination. Ninety-seven dogs, not vaccinated within 1 year before enrollment, were vaccinated with a modified live CDV vaccine. A measurement of the antibodies was performed before vaccination (day 0), on day 7, and 28 after the vaccination by virus neutralization. A response to vaccination was defined as a ≥4-fold titer increase by day 28. Fisher’s exact test was used to determine factors associated with a lack of antibodies and vaccination response. In total, 94.8% of the dogs (92/97; CI 95%: 88.2–98.1) had antibodies (≥10) prior to vaccination. A response to vaccination was not observed in any dog. Five dogs were considered humoral non-responders; these dogs neither had detectable antibodies before, nor developed antibodies after vaccination. Young age (<2 years) was significantly associated with a lack of pre-vaccination antibodies (p = 0.018; OR: 26.825; 95% CI: 1.216–1763.417). In conclusion, necessity of re-vaccination in adult healthy dogs should be debated and regular vaccinations should be replaced by antibody detection.
  • Zugangsstatus: Freier Zugang
  • Rechte-/Nutzungshinweise: Namensnennung (CC BY)